Company: VCYT
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001384101-25-000130
Chunk: 89

Company: VERACYTE, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 8
Chunk 89
---
 segment expenses and reconciliation to income from operations was as follows (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2025202420252024Revenue:Testing revenue$127,756 $109,536 $357,328 $306,809 Product revenue3,301 3,188 10,479 10,631 Biopharmaceutical and other revenue815 3,136 8,702 9,692 Total revenue131,872 115,860 376,509 327,132 Cost of revenue:Cost of testing revenue:Laboratory supplies and reagents expense14,766 13,887 43,134 39,131 Sample collection expense3,078 3,663 9,398 9,884 Compensation expense6,273 5,743 17,906 16,097 Other cost of testing revenue (1)6,456 2,797 14,017 9,122 Allocation of facilities and IT expenses3,204 2,939 9,989 8,694 Total cost of testing revenue33,777 29,029 94,444 82,928 Cost of product revenue:Product costs1,050 545 1,864 2,436 License fees and royalties257 270 888 1,021 Other cost of product revenue (2)1,672 750 2,980 2,372 Allocation of facilities and IT expenses36 227 454 481 Total cost of product revenue3,015 1,792 6,186 6,310 Cost of biopharmaceutical and other revenue:Compensation expense426 1,424 3,318 4,958 Other cost of biopharmaceutical and other revenue (3)612 1,024 3,118 3,244 Allocation of facilities and IT expenses53 664 925 1,560 Total cost of biopharmaceutical and other revenue1,091 3,112 7,361 9,762 Intangible asset amortization - cost of revenue2,707 2,917 7,959 8,741 Gross profit91,282 79,010 260,559 219,391 Operating expenses:Research and development:Compensation expense9,028 8,906 27,840 26,356 Direct